DIVINCELL

DIVINCELL is a BioPharmaceutical NanoMedicine company pioneering a novel drug delivery technology for the treatment of cancer and genetic diseases.

DIVINCELL offers innovative solutions to tackle nucleic acid/protein/peptide-based drug cellular uptake limitations, based on 20 years of research in the field of transfection. DIVINCELL has developed a patented technological platform of modular peptide "nanocages" that can guide and deposit the active molecule inside diseased cells without affecting the biological balance of healthy cells. The therapeutics developed by DIVINCELL have been validated using cancer and other therapeutic models (hemophilia, metabolic disorders) and provided an efficient alternative to existing drug delivery methods for a wide range of diseases.

DIVINCELL is developing and plans to commercialize its innovative drug delivery platform through strategic relationships with established laboratories and pharmaceutical companies. This breakthrough technology will have therapeutic potential enabling optimization of treatment accuracy and increasing patient safety.

Our mission at DIVINCELL is to have a major impact on human health by providing new and more effective treatments for various severe diseases whose therapeutic options remain limited.